ZyVersa Therapeutics EBIT

ZyVersa Therapeutics (ZVSA) currently reports a EBIT of $-25B as of March 2026. That compares with $-4.4B in the prior-year period — down 458.0% year over year. That is below the sector sector average of $-69M. Use the charts on this page to explore ZyVersa Therapeutics's EBIT history and peer comparisons.

ZyVersa Therapeutics's EBIT decreased from $-4.4B to $-25B — a 458.0% year-over-year decrease (period ending March 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

ZyVersa Therapeutics's EBIT of $-25B is lower than the its sector sector average of $-69M. That is roughly 35621.2% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

ZyVersa Therapeutics reported $-25B in EBIT as of March 2026. That compares with $-4.4B in the prior-year period — down 458.0% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current EBIT of $-25B, then check the historical chart for trend and the peer comparison chart for relative positioning. The sector average is $-69M. From there, open related valuation or income-statement pages for ZyVersa Therapeutics, and consider following ZVSA for alerts when major investors trade the stock.